Introduction

45
The wild mandrake or May Apple (Podophyllum peltatum), which was used in traditional native 46
American medicine, contains the natural product podophyllotoxin (1) . Podophyllotoxin itself proved to 47 be too toxic for human use, but the synthetic derivative etoposide (also known as VP-16) was approved 48 for cancer treatment in 1983. Etoposide acts by binding to topoisomerase II (2), an enzyme that can 49 relax DNA supercoiling, insert or remove knots, and catenate or decatenate DNA. It catalyzes an ATP-50 dependent cycle in which both strands of one DNA helix are broken, followed by passage through this 51 break of a second helix and religation of the breaks in the first. By inhibiting the religation step,etoposide and other anti-cancer agents such as doxorubicin create double-strand breaks. They can also 53 cause trapping of complexes in which tyrosine residues of the topoisomerase II homodimer remain 54 covalently attached to phosphate groups of the nucleotide at the 5' end of a DNA break, interfering with 55 subsequent DNA replication and transcription (3). Since topoisomerase II function is particularly 56 crucial during S phase when DNA is being replicated, rapidly proliferating cells (including tumor cells) 57 are more susceptible to cell death induced by etoposide than quiescent cells. 58
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status expressed in 59 essentially all eukaryotic cells, which occurs universally as heterotrimeric complexes comprising 60 catalytic  subunits and regulatory  and  subunits (4-6). AMPK is activated by phosphorylation of a 61 conserved threonine residue within the activation loop of the kinase domain on the  subunit, usually 62 referred to as Thr172. Thr172 is phosphorylated in vivo by a complex containing the tumor suppressor 63 kinase LKB1, or by Ca 2+ /calmodulin-dependent protein kinase kinases (CaMKKs), especially 64
CaMKK2 (4-6). The LKB1 complex appears to be constitutively active, but displacement of ATP by 65 AMP at two or more sites on the regulatory  subunit of AMPK leads to increased net Thr172 66 phosphorylation. This occurs because AMP binding triggers conformational changes that promote 67
Thr172 phosphorylation by LKB1 and inhibit Thr172 dephosphorylation by protein phosphatases, with 68 these effects being mimicked by ADP (7, 8); binding of AMP (but not ADP) also causes further 69 allosteric activation (9). Because increases in the cellular ADP:ATP ratio (signifying energy deficit) are 70 always accompanied by even larger increases in the AMP:ATP ratio, these three effects allow AMPK 71 to act as an ultrasensitive sensor of cellular energy status. The CaMKK2-AMPK pathway appears to be 72 activated solely by increases in intracellular Ca 2+ , which can be caused by addition to cells of Ca 2+ 
73
ionophores such as A23187, or by hormones or cytokines that increase intracellular Ca 2+ (4-6). 74
Each AMPK subunit exists as multiple isoforms (1/2, 1/2, 1/2/3) encoded by multiple genes 75 (PRKAA1/2, PRKAB1/2, PRKAG1/2/3). Intriguingly, while the PRKAA2 gene (encoding 2) is quite 76 often mutated in human cancers, consistent with the idea that it helps to exert the tumor suppressor role 77 of LKB1, the PRKAA1 and PRKAB2 genes (encoding 1 and 2) are frequently amplified instead, 78
suggesting that their amplification may be selected for because they promote tumor formation (5, 10).
The reason for the distinct behaviors of these AMPK-encoding genes in human cancers has been 80
unclear. 81
Fu et al (11) reported that etoposide activated AMPK, and claimed that the effect was dependent on 82 the protein kinase ataxia-telangiectasia mutated (ATM), because it appeared to be absent in ATM-83 deficient cells. ATM is a member of the phosphatidylinositol 3-kinase-like kinase (PIKK) family, with 84 the genetic disorder ataxia-telangiectasia being caused by loss-of-function mutations in the ATM gene. 85 ATM is activated in normal cells by double strand breaks in DNA, such as those induced by etoposide. 86
Once activated, ATM autophosphorylates on Ser1981, and phosphorylates downstream targets such as 87 the histone variant, H2AX, and Structural Maintenance of Chromosomes Protein-1 (SMC1); these 88 events can be used as biomarkers both for ATM activation and for DNA damage (12). ATM also 89 phosphorylates LKB1 at Thr366 (13), and it was reported that activation of AMPK by etoposide in 90 prostate cancer cells was reduced by shRNA-mediated knockdown of either ATM or LKB1 (14), 91
suggesting the existence of a kinase cascade from ATM to LKB1 to AMPK. Arguing against this, 92 however, etoposide still activated AMPK in the LKB1-null HeLa cell line (11), while ionizing radiation 93 (which causes double stranded DNA breaks and also activates ATM) activates AMPK in another 94
LKB1-null tumor line, A549 cells (15). 95
To address these discrepancies, we investigated the mechanism by which etoposide activates 96 AMPK. We show that activation of AMPK is restricted to the 1 isoform within the nucleus, and does 97 not require ATM or LKB1 but is dependent on CaMKK2 and triggered by increases in nuclear Ca 2+ .
98
We also show that prior activation of either isoform enhances cell survival during etoposide treatment. 99
These results not only provide a potential explanation for the findings that the gene encoding AMPK-100 1 (but not -2) is amplified in some human cancers, but also suggest that pharmacological inhibitors 101 of AMPK might make tumor cells more sensitive to death induced by DNA-damaging treatments, and 102 might therefore be useful adjuncts to chemotherapy or radiotherapy. If these inhibitors were 1-103 selective, this might avoid potential systemic side effects caused by inhibition of 2 complexes.
Clonogenic and MTT survival assays 156
For clonogenic survival assays, cells were seeded into 6 well plates at equal density and treated at 40-157 80% confluence with vehicle control or different concentrations of drug for 24 hr. Cells were 158 trypsinized in 0.5 ml of trypsin:EDTA for 5 min and then diluted with 1 ml of complete medium. The 159 cells in the control flask were counted using a hemocytometer under a microscope and 2000 cells 160 seeded in triplicate into 10 cm dishes containing 10 ml of medium. The same volume of cell suspension 161 was aspirated from the treated flasks and seeded in triplicate into 10 cm dishes also containing 10 ml of 162 medium. The dishes were placed at 37 ºC in an incubator for 10-15 days. On last day, the medium was 163 aspirated; the cells were fixed with ice-cold methanol for 10 min and stained with 0.3% w/v methylene 164 blue in methanol for 10 min. The dishes were washed with de-ionised water and the number of colonies 165 counted manually. 166
For MTT assays, cells were seeded in 12 well plates until 40-80% confluence and treated for 48 hr. 167
The cells were then incubated with 0.5% of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 168 bromide (MTT) for 3 hr. The growth medium was aspirated off and formazan crystals were dissolved 169 in 500 µl of acidified isopropanol. The intensity was measured by spectrophotometry at 570 nm. 170
Cell cycle analysis 171
Cells were seeded in 6 cm dishes until 40-80% confluence and treated for 16-18 hr. Cells were 172 trypsinized and the cells were pelleted, transferred into 5 ml Falcon tubes and washed with PBS 173 containing 1% fetal calf serum and 0.1 mM EDTA. The cells were then fixed with ice-cold 70% 174 ethanol for >2 hr. The cells were washed twice in the PBS buffer and stained with propidium iodide 175 (diluted 1 in 20 in the PBS buffer) with RNAse added to digest RNA. Cell cycle analysis was 176 performed on the Calibur flow cytometer and analysis performed using Flow Jo software. 177
Additional analytical procedures 178
SDS-PAGE was performed using precast Bis-Tris 4-12% gradient polyacrylamide gels in the MOPS 179 buffer system (Invitrogen). Proteins were transferred to nitrocellulose membranes (BioRad) using the 180 Xcell II Blot Module (Invitrogen). Membranes were blocked for 1 hr in Tris-buffered saline (TBS) 181 containing 5% (w/v) non-fat dried skimmed milk. The membranes were probed with appropriateantibody (0.1-1 μg/ml) in TBS-Tween and 2% (w/v) non-fat dried skimmed milk. Detection was 183 performed using secondary antibody (1 g/ml) coupled to IR 680 or IR 800 dye, and the membranes 184 scanned using the Li-Cor Odyssey IR imager. 185
Presentation of data and statistical analysis 186
Significances of differences were estimated using GraphPad Prism 6 for Mac OSX, using Student's t 187 test, 1-way or 2-way ANOVA as appropriate. Unless stated otherwise, Sidak's multiple comparison test 188 was used for post-hoc analysis. Numbers of replicates (n) refer to biological replicates, i.e. the number 189 of independent cell cultures analyzed. Significance of differences are indicated as follows: *P<0.05, 190 **P<0.01, ***P<0.001, ****P<0.0001 or †P<0.05, † †P<0.01, † † †P<0.001, † † † †P<0.0001; ns, not 191
significant. 192
Results
193
AMPK activation by etoposide does not require LKB1 194
We initially studied the effects of etoposide in cell lines expressing LKB1, including the human 195 embryonic kidney cell line, HEK-293. Surprisingly, we could not detect significant AMPK activation 196 in these cells using kinase assays, although it could be readily observed in two LKB1-null tumor cell 197 lines, i.e. HeLa (cervical cancer) and G361 (melanoma) cells. We could also observe AMPK activation 198 in immortalized mouse embryo fibroblasts (MEFs), which do express LKB1 (Fig. 1A) . 199
In HeLa cells, AMPK activation following addition of 30 µM etoposide was quite slow and 200 relatively modest in extent, becoming significant by 6-9 hours and reaching a maximum of 2-to 3-fold 201 after 18 hours (see Fig. 5A ). Infusion of high-dose etoposide in humans results in peak plasma 202 concentrations ranging from 50-200 µM (23), and AMPK activation after 16 hr treatment of HeLa cells 203 occurred at etoposide concentrations from 30 to 300 µM (Fig. 1B) . AMPK activation was associated 204 with increased Thr172 phosphorylation, by 1.8 ± 0.3-fold (n.s.), 2.2 ± 0.3-fold (P <0.05) and 2.3 ± 0.3-205 fold (P <0.05) at 30, 100 and 300 µM etoposide respectively (mean ± SEM, n = 6), and with 206 phosphorylation of the ATM substrate SMC1, although phosphorylation of the latter appeared to be 207 saturated at 30 µM (Fig. 1B) . As expected, activation and Thr172 phosphorylation of AMPK was alsoobserved following treatment of HeLa cells with the Ca 2+ ionophore A23187 (which activates the 209 upstream kinase CaMKK2) although the degree of activation was larger than that obtained with 210 etoposide. However, A23187 treatment did not lead to phosphorylation of SMC1, suggesting that ATM 211 was not activated by increasing cellular Ca 2+ (Fig. 1B) . Very similar effects of etoposide and A23187 212 were observed in G361 cells (Fig. 1C) , where the effects of etoposide on Thr172 phosphorylation were 213 2.1 ± 0.1-fold (n.s.), 3.5 ± 0.4-fold (P <0.001) and 3.7 ± 0.5-fold (P <0.001) at 30, 100 and 300 µM 214 respectively (mean ± SEM, n = 4). 215 AMPK activation by etoposide occurs primarily within the nucleus 216 cytoplasmic fluorescence is shown in Fig. 2B , left-hand panels (n = 10). As expected, large increases 220 (13-fold) in nuclear staining were obtained with the anti-pATM antibody after treatment with 221 etoposide, but not A23187. By contrast, large increases in nuclear staining were obtained with anti-222 pT172 antibody after treatment with either etoposide (13-fold) or A23187 (9-fold). Although A23187 223 also appeared to increase cytoplasmic pT172 staining in HeLa cells, this was not statistically 224 significant. Similar results were obtained with G361 cells, although in these cells A23187 did cause a 225 significant increase in cytoplasmic pT172 staining (Supplementary Fig. S1 ; quantification in Fig, 2C , 226 right). These results show that etoposide activates AMPK primarily in the nucleus, in both HeLa and 227
G361 cells. 228
Using the anti-pT172 antibody to detect AMPK activation in HeLa cells, fluorescence could be 229 observed in most nuclei after treatment for 18 hr with 100 µM etoposide, but was still observed in some 230 nuclei even at much lower etoposide concentrations (250 nM, Supplementary Fig. S2 , arrows); these 231 invariably corresponded with nuclei that were also positive for pATM, indicating the occurrence of 232
DNA damage. 233
Because basal Thr172 phosphorylation and AMPK activity is much higher in the cytoplasm of cells 234 that express LKB1 such as HEK-293 cells (24), we hypothesized that this might have been maskingchanges in the small pool of AMPK in the nucleus, explaining why we had not been able to initially 236 detect effects of etoposide in HEK-293 cells. Consistent with this, in control HEK-293 cells treated 237 with DMSO for 18 hr there was a diffuse cytoplasmic and nuclear fluorescence detected using anti-238 pT172 antibodies, such that it was difficult to distinguish the two compartments. Most cells also 239 displayed at least one perinuclear patch with more intense fluorescence; these appear to represent the 240 Golgi apparatus, since they stained with antibodies against the Golgi maker, GM130 (data not shown). 241
In cells treated with low etoposide concentrations (3 µM) the nuclei were more fluorescent than the 242 cytoplasm in some cells, once again corresponding with cells where the signal for nuclear pATM was 243 increased ( Supplementary Fig. S3 , arrows). 
AMPK activation by etoposide is specific for the 1 isoform 252
Because the sequences around Thr172 are identical in 1 and 2, the anti-pT172 antibody does not 253 distinguish the two AMPK catalytic subunit isoforms. However, human 1 (predicted mass 64,009 Da) 254 is slightly larger than 2 (62,319 Da), and the two isoforms can be resolved by SDS-PAGE. In Fig. 3A  255 we analyzed lysates from triplicate dishes of control and etoposide-treated HeLa cells by dual label 256
Western blotting using anti-pT172 antibodies labeled with IRDye 680 (red), and either 1-or 2-257 specific antibodies labeled with IRDye800 (green). In the upper blot (probed with anti-pT172 and anti-258 1) a single band appears predominantly green in the control lanes but becomes more yellow 259 (indicating increased Thr172 phosphorylation) after etoposide treatment. In the lower blot (probed 260 with anti-pT172 and anti-2) two bands are evident, an upper red band (1) that becomes more intense 261 after etoposide treatment, and a lower green band (2) whose intensity or color does not change. Theintensity in the pT172 (red) channel for 1 increased by 2.1 ± 0.1-fold (P <0.0001, n = 3) and 2.0 ± 263 0.1-fold (P = 0.0001, n = 3) in the upper and lower panels respectively, but was unchanged for 2. 264
These results show that Thr172 phosphorylation in response to etoposide occurs exclusively with the 265 1 isoform. To confirm this, we immunoprecipitated complexes from cell lysates of HeLa, G361 and 266 A549 cells using 1-or 2-specific antibodies, and measured kinase activity. The results (Fig. 3B-D ) 267
showed that 30-300 µM etoposide caused progressive activation of 1 complexes in all three cell types. 268
In HeLa and A549 cells etoposide failed to activate 2 complexes (Figs. 3B, 3D), while in G361 cells 269 the activity of 2 complexes was too low to measure reliably (Fig. 3C) . As a positive control, the Ca increased in response to A23187 (Fig. 3E) . 278
AMPK activation by etoposide requires CaMKK2 but not ATM 279
Since AMPK activation by etoposide in HeLa, G361 and A549 cells occurs in the absence of LKB1, 280 we examined whether it required the other well-established upstream kinase for AMPK, CaMKK2. Fig.  281 4A shows that the CaMKK2 inhibitor STO609 had no effect on etoposide-induced phosphorylation of 282 SMC1 (which is catalyzed by ATM), but did inhibit basal AMPK activity and Thr172 phosphorylation, 283 as well as the increases induced by etoposide (although at the concentration used it did not block the 284 effects of etoposide completely). 
4C). 293
To examine the involvement of ATM, we used the ATM-selective inhibitor KU-55933 (25). As 294 expected, KU-55933 blocked the phosphorylation of the ATM target SMC1 in response to etoposide. 295
However, although it appeared to cause a modest reduction in basal activity and Thr172 296 phosphorylation of AMPK, it did not prevent the increased AMPK activity and Thr172 297 phosphorylation caused by etoposide (Fig. 4D ). Thus, in these cells the regulation of AMPK by 298
AMPK activation is associated with increases in nuclear [Ca 2+ ] 300
Since activation and Thr172 phosphorylation of AMPK in response to etoposide required CaMKK2, 301
we suspected that it might be associated with increases in nuclear Ca 2+ concentration. ] were observed which followed a similar time course to changes 308 in AMPK activity, becoming significant at 6 hours and continuing to increase up to about 18 hours. 309
Cytoplasmic Ca 2+ did not exhibit such significant changes over the same time points (Fig. 5B) . 310
A23187 enhances cell survival during etoposide treatment via AMPK activation 311
Using the CRISPR-Cas9 system, we generated HeLa and G361 cells with single (1KO or 2KO) or 312 double (DKO) knockouts of the AMPK catalytic subunits. Fig. 6A shows that 1 and/or2 were 313 absent from the knockout HeLa cells as expected. Interestingly, 2 expression was markedly up-314 regulated in 1KO HeLa cells. We were unable to detect 2 by Western blotting in the G361 cells 315 (Fig. 6B) , consistent with our failure to detect it using kinase assays (see above). Also consistent withthis, phosphorylation of the AMPK target ACC in response to the AMPK activator H 2 O 2 (26) was 317 abolished in G361 cells by knockout of 1 only, although in HeLa cells this required knockout of both 318 1 and 2 (Fig. 6A/B) . 319
We next used two types of cell survival assay to assess the effect of prior AMPK activation by 320 A23187 on cell death induced by etoposide treatment of HeLa cells. Using MTT assays and treatment 321 for 48 hours (Fig. 6C) , 10 or 30 µM etoposide reduced cell survival to 21% and 7% of the DMSO 322 control, respectively. However, prior treatment with A23187 for 6 hours to activate AMPK 323 significantly enhanced cell survival to 47% and 14% of control, respectively. Similar protective effects 324 of A23187 were seen in 1KO and 2KO cells although the basal levels of survival appeared to be 325 slightly higher in these cells. However, the protective effect of A23187 treatment was completely 326 abolished in DKO cells at both etoposide concentrations. Similar results were obtained using the more 327 sensitive clonogenic survival assays (Fig. 6D) , although much lower concentrations of etoposide (100 328 and 250 nM) and shorter incubation times (18 hours) were used in these assays. One other difference 329 was that clonogenic survival was significantly lower in DKO cells at both 100 and 250 nM etoposide 330 even in cells not treated with A23187, an effect not seen using the MTT assays. Fig. 6E confirms using  331 anti-pSMC1 blots that ATM was activated to a similar extent at all four concentrations of etoposide 332 used in Figs. 6C and 6D, and that this was unaffected by single or double knockouts of the two AMPK 333 catalytic subunit isoforms. 334
We suspected that the protection against cell death provided by AMPK activation might be due to 335 G1 cell cycle arrest, which would reduce entry of cells into S phase where they would be more 336 vulnerable to DNA damage induced by etoposide. To confirm that A23187 induced G1 arrest in HeLa 337 cells, we treated them with or without A23187 in the presence of nocodazole (which prevents cells that 338 have already traversed the G1:S boundary from progressing through into the subsequent G1 phase). 339 isoform is capable of causing cell cycle arrest. However, a significant increase in G1:G2 ratio was not 342 observed in DKO cells.
Other treatments causing G1 arrest provided similar protection against etoposide 344
To test whether other treatments that caused G1 arrest would provide protection against etoposide-345 induced cell death, we initially used palbociclib (PBC, also known as PD332991), an inhibitor of the 346 cyclin-dependent kinases CDK4/CDK6 (27, 28). Interestingly, PBC did not cause cell cycle arrest in 347
HeLa cells (Fig. 7A) . However, in G361 cells PBC from 0.1 to 10 nM caused a progressive increase in 348 the proportion of G361 cells in G1 phase, with corresponding decreases in the proportions in S and 349 G2/M phases (Fig. 7B) . Tellingly, PBC did not protect against cell death induced by etoposide in 350 clonogenic survival assays in HeLa cells (Fig. 7C) , but provided marked protection in G361 cells (Fig.  351   7D) . We have shown previously that A23187 treatment of G361 cells causes a G1 arrest that is 352 To confirm that another agent that caused cell cycle arrest would protect HeLa cells against 356 etoposide, we used aphidicolin, which causes arrest in early S phase by inhibiting DNA polymerase- 357 (29). Unlike palbociclib, aphidicolin cause a marked arrest at the G1/S boundary (Fig. 7E ) and also 358 provided significant protection against cell death induced by etoposide in clonogenic survival assays 359 (Fig. 7F) . 360
Discussion
361
We have confirmed that the DNA-damaging agent etoposide activates AMPK in several different cell 362 lines as reported previously (11, 14), but also present new findings that AMPK activation by etoposide 363 occurs primarily in the nucleus, and is specific for complexes containing the 1 isoform of the catalytic 364 subunit even when 2 was also expressed, as in HeLa and A549 cells. Since these cells do not express 365 LKB1, our results rule out a role for that kinase. We show instead that the effect is catalyzed by the 366 alternate upstream kinase CaMKK2, since it was reduced either by the CaMKK inhibitor STO-609, or 367 by knocking down CaMKK2 using siRNA. The correlation between AMPK activation and nuclear 368 ] rather than any intrinsic change in CaMKK2 activity, although the source of the increasednuclear Ca 2+ , and the mechanism by which it is released in response to etoposide and/or DNA damage, 371 remains unclear. 372
We were initially unable to detect significant Thr172 phosphorylation or activation of AMPK by 373 etoposide in HEK-293 cells, which express normal levels of LKB1. However, we subsequently 374 observed increased Thr172 phosphorylation in the nuclei of HEK-293 cells by immunofluorescence 375 microscopy. We believe that we could not detect changes in global Thr172 phosphorylation or AMPK 376 activation in these cells because the high basal levels of these parameters in the cytoplasm (due to the 377 high basal activity of LKB1) were obscuring changes in the small pool of AMPK within the nucleus. 378
It was previously reported that AMPK activation by etoposide in a prostate cancer cell line (C4-2) 379 was reduced by knocking down ATM or LKB1 using RNAi (14). Since ATM had been previously 380 shown to phosphorylate LKB1 at Thr366 (13), it was proposed (14) that there was a kinase cascade 381 from ATM to LKB1 to AMPK. However, Thr366 phosphorylation has been reported to have no effect 382 on either the activity or the localization of LKB1 in G361 cells (13). Moreover, this mechanism cannot 383 explain the effects in the cells we studied because: (i) in HeLa cells, etoposide activated AMPK via a 384 mechanism that required CaMKK2, but not LKB1; (ii) although etoposide activated ATM in HeLa 385 cells, the ATM inhibitor KU-55933 did not prevent increased AMPK activity and Thr172 386 phosphorylation in response to etoposide, despite blocking phosphorylation of a known ATM target, 387
SMC1. 388
One interesting question raised by our study is why AMPK activation by etoposide is restricted to 389 nuclear 1 complexes. LKB1 is only catalytically active when it forms a complex with the accessory 390 subunits STRAD and MO25 (30), and association with these subunits causes its exclusion from the 391 nucleus (31), implying that LKB1 may only be able to activate cytoplasmic AMPK. Consistent with 392 CaMKK2 must be present in the nucleus, since if the effect was due to translocation of activatedAMPK, it should work equally well after treatment with 2-deoxyglucose or A23187. There is also 399 evidence that 2-containing complexes are activated primarily by the AMP-and LKB1-dependent 400 mechanism rather than the Ca 2+ /CaMKK2 mechanism in vivo. For example, conditional LKB1 401 knockout in skeletal and cardiac muscle prevented activation of 2-containing complexes in response 402 to contraction in skeletal muscle or ischemia in cardiac muscle, while having little or no effect on the 403 activity of 1-containing complexes (34, 35). The reasons for this apparent selectivity of upstream 404 kinases for 1 or 2-containing complexes in vivo remain unclear, because the LKB1:STRAD:MO25 405 complex (24) and CaMKK2 (36) phosphorylate and activate both 1-or 2-containing complexes in 406 cell-free assays, while treatment with the Ca 2+ ionophore A23187 can activate 2 complexes in intact 407 cells (Fig. 2B) . One possibility is that this isoform selectivity is due to different subcellular locations of 408 the upstream kinases and the AMPK complexes containing the different  isoforms. Both 1 and 2 409 contain well-defined nuclear export sequences (37), while nuclear localization sequences are less well-410 defined, although a short conserved basic sequence in 2 (also present in 1) has been proposed to 411 fulfill that role (38). If 1 complexes were more abundant than 2 complexes in the nuclei of 412 unstimulated HeLa or G361 cells, this might explain why only the former were activated by etoposide. 413
Arguing against this possibility, however, is evidence that it is 2 rather than 1 that is enriched in the 414 nucleus (39), although that was obtained using different cell types. Interestingly, etoposide treatment 415 did not cause phosphorylation of ACC at the AMPK site Ser79, unlike A23187 (Figs. 3E, 4A, 4C) . 416 ACC phosphorylation is a universally used biomarker for AMPK activation, and etoposide is the first 417 AMPK activator we have studied that does not trigger it. The obvious explanation is that etoposide 418 activates AMPK primarily in the nucleus, from which ACC (a large cytoplasmic protein) is excluded. 419
Another novel finding in our study was that prior elevation of intracellular Ca 2+ for 6 hours using the 420 Ca 2+ ionophore A23187 protected against cell death induced by etoposide, both in short-term MTT 421 assays and in clonogenic survival assays. In both cases, the effect was AMPK-dependent, because it 422 was eliminated in HeLa and G361 cells when both catalytic subunit isoforms (1 and 2) were 423 knocked out using the CRISPR-Cas9 system. Single knockouts did not abolish the effect in HeLa cells, 424
suggesting that either isoform is capable of exerting the protective effect, although we have found that 425 only 1 complexes are activated by etoposide. A caveat here, however, is that knockout of AMPK-1caused a marked up-regulation of AMPK-2 expression (Fig. 6A) , raising the possibility that over-427 expressed AMPK-2 might perform functions that endogenous levels might not. A notable difference 428 between the MTT and the clonogenic survival assays is that effects of etoposide on cell survival were 429 observed in clonogenic assays at much lower concentrations (100-250 nM, as opposed to 10-30 µM for 430 MTT assays). This is a common finding, and may occur because a low level of DNA damage, which 431 may be quite difficult to detect, is nevertheless sufficient to prevent clonal growth of single cells. 432
These findings to some extent turn the original view on the role of AMPK in cancer on its head. explain why the effect of the inhibitor differs between these two cell lines, since p16 is expressed at 475 much higher levels in HeLa than in G361 cells (50). 476
In summary, DNA-damaging treatments such as etoposide (11) and ionizing radiation (15) have 477 been previously reported to activate AMPK, and it was suggested that the effect of etoposide occurred 478 via a kinase cascade from ATM to LKB1 to AMPK (14). However, we show that the effect of 479 etoposide is independent of ATM and LKB1, and involves instead an increase in nuclear Ca 2+ that 480 causes activation of CaMKK2. AMPK activation is restricted to the 1 isoform and occurs within the 481 nucleus, so that phosphorylation of ACC, the classical marker for AMPK activation, is not observed.
Moreover, prior AMPK activation using A23187 in two different LKB1-null tumor cell lines protects 483 against cell death induced by etoposide, and this was AMPK-dependent because the effect was 484 abolished when both isoforms of AMPK were knocked out. Taken together with findings that AMPK-485 1 is required for growth of transformed mouse embryo fibroblasts as tumors in vivo (45) , and that the 486 gene encoding AMPK-1 is frequently amplified in human tumors (5, 10), this suggests that AMPK 487 inhibitors, and particularly selective inhibitors of AMPK-1, might be useful adjuncts to cytotoxic 488 drugs, and perhaps also radiotherapy, in human cancer. were analyzed by Western blotting using anti-pSMC1, total SMC1, anti-pT172 (phospho-624 AMPK) and a mixture of anti-1 and -2 antibodies. (C) As (B), but using G361 cells. 
